Our most advanced Tumor Defence Breaker, L-DOS47, is currently in clinical trials for the treatment of non squamous small cell lung cancer (NSCLC). The application of L-DOS47 in other disease indication such as colon, pancreas and breast cancer is also being considered. A second DOS47 candidate known as V-DOS47 targets the vascular epithelial growth factor receptor 2 is at preclinical development.
Helix is also developing a number of Tumor Attackers, CAR-T, that are potential treatment of hematological and solid tumors.
Learn more about our ongoing clinical trials at www.clinicaltrials.gov.